Amyloidosis natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
In amyloidosis, insoluble fibrils of [[amyloid]] are deposited in [[organs]], causing [[Multiple organ dysfunction syndrome|organ dysfunction]] and eventually death. [[Patient|Patients]] with amyloidosis may eventually suffer from [[heart failure]], [[nephrotic syndrome]], [[hepatomegaly]] and [[peripheral neuropathy]]. In primary amyloidosis, the [[survival rate]] depends upon the type of [[Organ (anatomy)|organ]] involvement and the [[hematological]] response to treatment. In AL amyloidosis, untreated individuals have the worst [[prognosis]]. In this group of patients, the [[median]] [[Survival rate|survival]] is one to two years. | |||
==Natural History | ==Natural History, Complications, and Prognosis== | ||
== | === Natural History === | ||
*In amyloidosis, insoluble fibrils of [[amyloid]] are deposited in the organs, causing organ dysfunction and eventually death.<ref name="pmid23227278">{{cite journal |vauthors=Baker KR, Rice L |title=The amyloidoses: clinical features, diagnosis and treatment |journal=Methodist Debakey Cardiovasc J |volume=8 |issue=3 |pages=3–7 |date=2012 |pmid=23227278 |pmc=3487569 |doi= |url=}}</ref> | |||
* In AL amyloidosis, untreated individuals have the worst [[prognosis]]. In this group of [[Patient|patients]], median [[Survival rate|survival]] is one to two years.<ref name="pmid11677276">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref> | |||
*[[Patient|Patients]] with amyloidosis may eventually suffer from [[heart failure]], [[nephrotic syndrome]], [[hepatomegaly]] and [[peripheral neuropathy]]. | |||
==Prognosis== | ===Complications=== | ||
* In primary (AL) amyloidosis survival rate depends on:<ref name="pmid22909024">{{cite journal |vauthors=Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A |title=Al amyloidosis |journal=Orphanet J Rare Dis |volume=7 |issue= |pages=54 |date=August 2012 |pmid=22909024 |pmc=3495844 |doi=10.1186/1750-1172-7-54 |url=}}</ref> | |||
** | In patients with amyloidosis, the most frequent complications include:<ref name="pmid26155101">{{cite journal |vauthors=Jerzykowska S, Cymerys M, Gil LA, Balcerzak A, Pupek-Musialik D, Komarnicki MA |title=Primary systemic amyloidosis as a real diagnostic challenge - case study |journal=Cent Eur J Immunol |volume=39 |issue=1 |pages=61–6 |date=2014 |pmid=26155101 |pmc=4439975 |doi=10.5114/ceji.2014.42126 |url=}}</ref> | ||
** The severity of | |||
** Haematological response to treatment | *[[Heart failure]] | ||
* The median survival of patients with AL amyloidosis is aproximately 3.8 years.<ref name="pmid21483018">{{cite journal |vauthors=Merlini G, Seldin DC, Gertz MA |title=Amyloidosis: pathogenesis and new therapeutic options |journal=J. Clin. Oncol. |volume=29 |issue=14 |pages=1924–33 |date=May 2011 |pmid=21483018 |pmc=3138545 |doi=10.1200/JCO.2010.32.2271 |url=}}</ref> | *[[Nephrotic syndrome]] | ||
* In primary (AL) amyloidosis 27% of patients | *[[Hepatomegaly]] | ||
* The major determinant of outcome in amyloidosis is the extent of cardiac involvement. | *[[Peripheral neuropathy]] | ||
** Cardiac amyloidosis is the cause of death in 75% of the patients who died, including sudden death in 25%. | |||
===Prognosis=== | |||
* In primary (AL) amyloidosis, survival rate depends on:<ref name="pmid22909024">{{cite journal |vauthors=Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A |title=Al amyloidosis |journal=Orphanet J Rare Dis |volume=7 |issue= |pages=54 |date=August 2012 |pmid=22909024 |pmc=3495844 |doi=10.1186/1750-1172-7-54 |url=}}</ref> | |||
** Type of organ involvement (amyloid heart disease is the main [[Prognostic|prognostic factor]]) | |||
** The severity of various [[Organ (anatomy)|organ]] involvement | |||
**[[Haematological|Hematological]] response to treatment | |||
* The [[median]] [[Survival rate|survival]] of [[Patient|patients]] with AL amyloidosis is aproximately 3.8 years.<ref name="pmid21483018">{{cite journal |vauthors=Merlini G, Seldin DC, Gertz MA |title=Amyloidosis: pathogenesis and new therapeutic options |journal=J. Clin. Oncol. |volume=29 |issue=14 |pages=1924–33 |date=May 2011 |pmid=21483018 |pmc=3138545 |doi=10.1200/JCO.2010.32.2271 |url=}}</ref> | |||
* In primary (AL) amyloidosis 27% of the [[Patient|patients]] die within 1 year of [[diagnosis]]. | |||
* The major determinant of outcome in amyloidosis is the extent of [[cardiac]] involvement. | |||
**[[Cardiac amyloidosis]] is the cause of death in 75% of the [[Patient|patients]] who died, including sudden death in 25%. | |||
==References== | ==References== | ||
Latest revision as of 21:30, 25 October 2019
|
Amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Amyloidosis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Amyloidosis natural history, complications and prognosis |
|
FDA on Amyloidosis natural history, complications and prognosis |
|
CDC on Amyloidosis natural history, complications and prognosis |
|
Amyloidosis natural history, complications and prognosis in the news |
|
Blogs on Amyloidosis natural history, complications and prognosis |
|
Risk calculators and risk factors for Amyloidosis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
In amyloidosis, insoluble fibrils of amyloid are deposited in organs, causing organ dysfunction and eventually death. Patients with amyloidosis may eventually suffer from heart failure, nephrotic syndrome, hepatomegaly and peripheral neuropathy. In primary amyloidosis, the survival rate depends upon the type of organ involvement and the hematological response to treatment. In AL amyloidosis, untreated individuals have the worst prognosis. In this group of patients, the median survival is one to two years.
Natural History, Complications, and Prognosis
Natural History
- In amyloidosis, insoluble fibrils of amyloid are deposited in the organs, causing organ dysfunction and eventually death.[1]
- In AL amyloidosis, untreated individuals have the worst prognosis. In this group of patients, median survival is one to two years.[2]
- Patients with amyloidosis may eventually suffer from heart failure, nephrotic syndrome, hepatomegaly and peripheral neuropathy.
Complications
In patients with amyloidosis, the most frequent complications include:[3]
Prognosis
- In primary (AL) amyloidosis, survival rate depends on:[4]
- Type of organ involvement (amyloid heart disease is the main prognostic factor)
- The severity of various organ involvement
- Hematological response to treatment
- The median survival of patients with AL amyloidosis is aproximately 3.8 years.[5]
- In primary (AL) amyloidosis 27% of the patients die within 1 year of diagnosis.
- The major determinant of outcome in amyloidosis is the extent of cardiac involvement.
- Cardiac amyloidosis is the cause of death in 75% of the patients who died, including sudden death in 25%.
References
- ↑ Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
- ↑ Khan MF, Falk RH (November 2001). "Amyloidosis". Postgrad Med J. 77 (913): 686–93. PMC 1742163. PMID 11677276.
- ↑ Jerzykowska S, Cymerys M, Gil LA, Balcerzak A, Pupek-Musialik D, Komarnicki MA (2014). "Primary systemic amyloidosis as a real diagnostic challenge - case study". Cent Eur J Immunol. 39 (1): 61–6. doi:10.5114/ceji.2014.42126. PMC 4439975. PMID 26155101.
- ↑ Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A (August 2012). "Al amyloidosis". Orphanet J Rare Dis. 7: 54. doi:10.1186/1750-1172-7-54. PMC 3495844. PMID 22909024.
- ↑ Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.